Delta Crystallon

Delta Crystallon is a privately owned biopharmaceutical company dedicated to the development of highly selective biotherapeutics for neurodegenerative disorders. The Company’s lead product is DC-TAB, a recombinant form of the human small heat shock protein alpha B-crystallin. Delta Crystallon is currently finalizing a randomized, double blind, placebo-controlled clinical Phase IIa study in relapsing-remitting multiple sclerosis patients. Strongly encouraged by the preliminary outcome of this study, preparations are underway for a next Phase IIb study. Recent developments have inspired Delta Crystallon to additionally target the orphan indications amyotrophic lateral sclerosis and progressive supranuclear palsy. Delta Crystallon was founded in 2008, and extends its cutting-edge internal R&D with a strong network of external expertise, both corporate and academic. Combining its own strengths with the complementary capabilities of partners that are the best in their field ensures the highest level of quality and expertise to support Delta Crystallon’s development program